In vitro evaluation of A-56619 and A-56620, two new quinolones.
The in vitro activities of two new aryl-fluoroquinolones (A-56619 and A-56620) were compared with those of ciprofloxacin, ofloxacin, enoxacin, and norfloxacin. All six quinolones had broad spectra of antibacterial activity; the streptococci, Pseudomonas maltophilia, and Pseudomonas cepacia were the least susceptible. A-56619, A-56620, and chloramphenicol had similar activity against anaerobic bacteria. With both drugs, a low frequency of resistant variants (less than 10(-8)) was observed. By regression analysis, A-56619 MICs correlated best with ofloxacin MICs and A-56620 was most similar to ciprofloxacin.
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001419:Bacteria / Q000187:drug effects*; D001421:Bacteria, Anaerobic / Q000187:drug effects; D002939:Ciprofloxacin / Q000031:analogs & derivatives; D004352:Drug Resistance, Microbial; D015365:Enoxacin; D024841:Fluoroquinolones; D008826:Microbial Sensitivity Tests; D009268:Nalidixic Acid / Q000494:pharmacology; D009287:Naphthyridines / Q000494:pharmacology; D009643:Norfloxacin / Q000494:pharmacology; D015242:Ofloxacin; D010078:Oxazines / Q000494:pharmacology; D010879:Piperazines / Q000494:pharmacology*; D011804:Quinolines / Q000494:pharmacology*
D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D009287:Naphthyridines; D010078:Oxazines; D010879:Piperazines; D011804:Quinolines; D015365:Enoxacin; D009268:Nalidixic Acid; D002939:Ciprofloxacin; C047225:difloxacin; D015242:Ofloxacin; D009643:Norfloxacin; C047224:sarafloxacin